Welcome to our dedicated page for Centessa Pharmaceuticals Plc news (Ticker: CNTA), a resource for investors and traders seeking the latest updates and insights on Centessa Pharmaceuticals Plc stock.
Centessa Pharmaceuticals Plc (Nasdaq: CNTA) is a clinical-stage biopharmaceutical company advancing novel therapies for sleep-wake disorders and immuno-oncology through its innovative asset-centric R&D model. This dedicated news hub provides investors and industry observers with essential updates on the company’s progress in developing transformational medicines.
Our curated collection of CNTA news offers timely access to official press releases, clinical trial milestones, and regulatory developments. Track updates on key programs including ORX750 for narcolepsy, LB101 immuno-oncology candidates, and strategic R&D decisions. The platform serves as a centralized resource for understanding Centessa’s scientific advancements and business trajectory.
Users will find verified information on trial results, partnership announcements, and technology innovations like the LockBody® platform. Content is organized to help stakeholders monitor progress across therapeutic areas while maintaining perspective on the company’s unique operational structure. All materials are sourced directly from company communications and reputable financial news outlets.
Bookmark this page for efficient tracking of CNTA’s evolving pipeline and corporate developments. Combine these updates with SEC filings and earnings materials for comprehensive analysis of Centessa’s position in the competitive biopharmaceutical landscape.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced the appointment of Antoine Yver, MD, MSc, as Executive Vice President and Chairman of Development, and Javad Shahidi, MD, MSc, as Chief Medical Officer. Dr. Yver will oversee overall development strategy, while Dr. Shahidi will manage clinical development teams. CEO Saurabh Saha emphasized the recruitment of talent amid plans for registrational trials and entry of multiple assets into clinical phases. Dr. Shahidi's previous role at Daiichi Sankyo involved leading significant oncology programs.
Centessa Pharmaceuticals (Nasdaq: CNTA) and its subsidiary Palladio Biosciences have initiated dosing in the pivotal Phase 3 ACTION Study, evaluating lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD). This trial aims to enroll ~1,350 participants across 200 sites in over 20 countries, with completion expected in H2 2023. Positive results may lead to a New Drug Application (NDA) submission post the double-blind study phase. Lixivaptan's unique profile may mitigate liver toxicity issues associated with existing ADPKD therapies, enhancing its therapeutic potential.
Centessa Pharmaceuticals (CNTA) has initiated the global ACTION Study, a pivotal Phase 3 clinical trial investigating lixivaptan as a treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). With up to 1,350 subjects, the double-blind trial aims to assess lixivaptan's efficacy in slowing renal function decline over 52 weeks. Initial safety data from four subjects in the ALERT Study show successful titration of lixivaptan without liver toxicity, while a new patent protects lixivaptan use in ADPKD until 2038. The first subject is expected to be dosed in Q1 2022.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced its upcoming addition to the NASDAQ Biotechnology Index, effective December 20, 2021. This index includes companies classified as Biotech or Pharma that meet specified criteria. The announcement reflects Centessa's innovative, asset-centric model aimed at developing impactful medicines across multiple therapeutic areas such as oncology and immunology. This addition may enhance Centessa's visibility and investor interest, potentially influencing its stock performance positively.
IMIDomics Inc. has established its Scientific and Business Advisory Boards to enhance its mission in developing precision medicines for immune-mediated inflammatory diseases (IMIDs) such as lupus and rheumatoid arthritis. The boards consist of leading experts including Dan Littman and Luisa Salter-Cid, aiding IMIDomics in leveraging its Precision Discovery Engine, which integrates extensive clinical data to innovate therapies for IMIDs. CEO Juan Harrison emphasizes the importance of advancing treatment options for these complex and often undertreated conditions.
Epizyme, Inc. has announced the appointment of two new members to its Board of Directors: Roy A. Beveridge, M.D., a clinical oncology executive, and Carol Stuckley, M.B.A., a seasoned pharmaceutical and financial leader. Beveridge brings over 30 years of experience in oncology and healthcare policy, while Stuckley offers 25 years of financial expertise from Pfizer. The company also announced the resignation of Andrew R. Allen, M.D., Ph.D., effective November 16, 2021. The leadership changes aim to enhance Epizyme's focus on epigenetic therapies and support its growth trajectory.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced promising topline results from a proof-of-concept study of SerpinPC in severe hemophilia A and B, showing an 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds. The company also provided proof-of-mechanism data for ZF874 in Alpha-1 Antitrypsin Deficiency. A $300 million financing facility was secured with Oberland Capital, strengthening the company's financial position. Centessa incurred a net loss of $40.2 million for Q3 2021, with cash and equivalents at $653.4 million, anticipated to fund operations until mid-2024.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will present at two upcoming investor conferences. The first is the Jefferies London Healthcare Conference on November 18, 2021, where the presentation will be available on-demand starting at 3:00 AM ET. The second is the Evercore ISI HealthCONx Conference on December 2, 2021, featuring a fireside chat at 4:20 PM ET. Access to live webcasts and archives will be available on the Centessa investor relations website.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced proof-of-mechanism data from its Phase 1 study of ZF874 for treating Alpha-1 Antitrypsin Deficiency (AATD). The study showed increases in functional Z-A1AT levels exceeding 11 micromolar in patients with the PiZZ genotype. One subject displayed reversible elevation in liver enzymes, prompting the company to expedite enrollment for upcoming studies. The expected Phase 2 study is set to refine dosing and is anticipated to start in 2Q 2022.
Centessa Pharmaceuticals (CNTA) and Schrödinger are collaborating to discover novel therapeutics targeting the orexin-2 receptor (OX2R), which plays a critical role in sleep disorders like narcolepsy. This partnership allows Orexia to utilize Schrödinger’s advanced computational platform, enhancing drug discovery capabilities. Orexia aims to leverage this collaboration for the development of orexin agonists addressing narcolepsy type 1 and other conditions characterized by excessive daytime sleepiness. The agreement includes milestone payments and royalties for Schrödinger.
